205 - Why Less Than 20% of Companies Have Started Quality 4.0

205 - Why Less Than 20% of Companies Have Started Quality 4.0

Nearly two-thirds of companies believe Quality 4.0 will transform their operations in the next five years yet fewer than 20% have started, and most haven’t even reached the planning stage. In this conversation, Larry Mager breaks down what Quality 4.0 really is, why life sciences lag other industries, and how to move from compliance-only thinking to a business-driving quality strategy. We cover digital twins, data continuity, culture change, and Larry’s Quantum Quality Management (QQM) framework as a practical roadmap.Timestamps00:00 Introduction to Quality 4.000:20 Defining Quality 4.001:39 The Role of Quality Professionals02:50 Industry Examples & Cultural Differences04:04 Implementing Quality 4.0 (people, process, tech)08:49 The Digital Twin Concept (why legacy EQMS falls short)13:34 The Importance of a Roadmap 30:28 Quantum Quality Management (5-phase framework)35:05 Final Thoughts & Contact InformationLarry Mager is the Founder and Principal at MGMT-CTRL, where he specializes in applying strategic quality management that goes beyond mere compliance. With three decades of experience in the medical device industry, Larry has held leadership roles spanning quality systems, operations management, CAPA, supplier control, risk management, lean manufacturing, and continuous improvement. He is also the architect of the Quantum Quality Management (QQM) framework, a phased methodology that marries people, process, and technology to help organizations adopt Quality 4.0, drive operational excellence, and use quality as a strategic business advantage.Subhi Saadeh is a Quality Professional and host of Let's Combinate. With a background in Quality, Manufacturing Operations and R&D he's worked in Large Medical Device/Pharma organizations to support the development and launch of Hardware Devices, Disposable Devices, and Combination Products for Vaccines, Generics, and Biologics. Subhi serves currently as the International Committee Chair for the Combination Products Coalition(CPC) and as a member of ASTM Committee E55 and also served as a committee member on AAMI's Combination Products Committee.For questions, inquiries or suggestions please reach out at letscombinate.com or on the show's LinkedIn Page.

Tämä jakso on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi jakso saattaa sisältää mainontaa.

Jaksot(245)

231 - Audit Findings Explained: Nonconformity vs Observation (CQA)

231 - Audit Findings Explained: Nonconformity vs Observation (CQA)

This is a lesson out of my ASQ CQA course with Andy Robertson, on how to write and classify audit findings.Access the full CQA course here: https://cqeacademy.teachable.com/p/the-cqa-master-class-cour...

25 Maalis 11min

230 - How Pharma Misses Critical Market Signals with Joe Luminiello

230 - How Pharma Misses Critical Market Signals with Joe Luminiello

In this episode of Let’s ComBinate, Subhi Saadeh sits down with Joseph Luminiello, CEO and Co-Founder of RCG Intel, to break down how competitive intelligence is actually used in biopharma and why mos...

23 Maalis 30min

229 -Outsourcing Analytical Testing: What Sponsors Get Wrong in Combination Products

229 -Outsourcing Analytical Testing: What Sponsors Get Wrong in Combination Products

In this episode of Let’s Combinate, Subhi Saadeh speaks with Jen Riter about analytical method validation for drug device combination products. The discussion explores how traditional drug analytical ...

11 Maalis 31min

228 - ICH Q5 EXPLAINED: Why Regulators Treat Biologics Differently

228 - ICH Q5 EXPLAINED: Why Regulators Treat Biologics Differently

Continuing the ICH Q series with ICH Q5. This episode explains why Q5 exists, how to read it, and what it means for combination products. Q5 addresses quality challenges unique to biologics made in li...

4 Maalis 6min

227 - When Should You Open a CAPA? Triggers, Human Error, and Investigation Basics

227 - When Should You Open a CAPA? Triggers, Human Error, and Investigation Basics

Subhi Saadeh sits down with Georg Digel, founder of Elevate CAPA, to break down what should trigger CAPA, and how to investigate the right way using practical tools and better problem statements.Times...

24 Helmi 28min

226 - Navigating China NMPA Medical Device Requirements | Standards, GMP Updates, Agents & Classification

226 - Navigating China NMPA Medical Device Requirements | Standards, GMP Updates, Agents & Classification

In this episode, Subhi Saadeh sits down with Elaine (Yi Ling Tan), Creator and Principal Consultant at MedTech Chopsticks, to break down China medical device market access and regulatory compliance un...

18 Helmi 29min

226 - ICH Q4 Explained: How Pharmacopeial Methods Are Accepted Across Regions

226 - ICH Q4 Explained: How Pharmacopeial Methods Are Accepted Across Regions

In this episode of the ICH Q series, Subhi Saadeh covers ICH Q4, which focuses on pharmacopeial harmonization. He explains why ICH Q4 exists, the problem it was created to solve, and how the ICH Q4 fr...

11 Helmi 8min

225 - ICH Q3A, Q3B, Q3C, Q3D and Q3E - EXPLAINED in 10 Minutes

225 - ICH Q3A, Q3B, Q3C, Q3D and Q3E - EXPLAINED in 10 Minutes

In this episode of Let’s ComBinate: Drugs + Devices, host Subhi Saadeh breaks down ICH Q3, the family of guidelines that define how impurities are identified, evaluated, and controlled in drug substan...

4 Helmi 9min

Suosittua kategoriassa Tiede

rss-mita-tulisi-tietaa
rss-poliisin-mieli
tiedekulma-podcast
rss-tiedetta-vai-tarinaa
utelias-mieli
docemilia
sotataidon-ytimessa
filocast-filosofian-perusteet
menologeja-tutkimusmatka-vaihdevuosiin
rss-bios-podcast
rss-ranskaa-raakana
rss-duodecim-lehti
rss-duokkari-ekstra
rss-astetta-parempi-elama-podcast
rss-metsantuntijat-podcast
rss-ilmasto-kriisissa
rss-ylistys-elaimille
rss-sosiopodi